Answers are grounded in this paper and cite their sources.
Estimating time-savings benefits of lecanemab treatment in early Alzheimer's disease, suggesting insights for clinical decisions.
Estimate the 10-year time-savings benefits of lecanemab in early AD, to provide clarity on long-term benefits of continuous treatment and provide meaningful information for clinical decision-making.
No takes yet. Share an insight, caveat, or question.
Whetten et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: